Selected article for: "account age and adaptive immunity"
Author: Stephens, Laura M.; Varga, Steven M.
Title: Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population
  • Cord-id: 89fg7e6v
  • Document date: 2021_6_9
    • ID: 89fg7e6v
    Snippet: Respiratory syncytial virus (RSV) is most commonly associated with acute lower respiratory tract infections in infants and children. However, RSV also causes a high disease burden in the elderly that is often under recognized. Adults >65 years of age account for an estimated 80,000 RSV-associated hospitalizations and 14,000 deaths in the United States annually. RSV infection in aged individuals can result in more severe disease symptoms including pneumonia and bronchiolitis. Given the large dise
    Document: Respiratory syncytial virus (RSV) is most commonly associated with acute lower respiratory tract infections in infants and children. However, RSV also causes a high disease burden in the elderly that is often under recognized. Adults >65 years of age account for an estimated 80,000 RSV-associated hospitalizations and 14,000 deaths in the United States annually. RSV infection in aged individuals can result in more severe disease symptoms including pneumonia and bronchiolitis. Given the large disease burden caused by RSV in the aged, this population remains an important target for vaccine development. Aging results in lowered immune responsiveness characterized by impairments in both innate and adaptive immunity. This immune senescence poses a challenge when developing a vaccine targeting elderly individuals. An RSV vaccine tailored towards an elderly population will need to maximize the immune response elicited in order to overcome age-related defects in the immune system. In this article, we review the hurdles that must be overcome to successfully develop an RSV vaccine for use in the elderly, and discuss the vaccine candidates currently being tested in this highly susceptible population.

    Search related documents:
    Co phrase search for related documents
    • acid ribonucleic and acute respiratory illness: 1, 2
    • acid ribonucleic and adaptive immune response: 1
    • acid ribonucleic and adenovirus vector: 1, 2
    • acute respiratory illness and adaptive immune response: 1
    • acute respiratory illness and additional vaccine: 1, 2, 3
    • acute respiratory illness and adenovirus serotype: 1
    • adaptive immune response and adenovirus vector: 1, 2
    • adaptive immune response and adjuvant addition: 1
    • adaptive immune response and adjuvant as01: 1
    • additional vaccine and adenovirus vector: 1
    • adenovirus vector and adjuvant as01: 1